[Bretylium tosylate as an anti-arrhythmic drug].
With the help of an analysis of the world literature pharmacological, pharmacokinetic and electrophysiological properties as well as the possibilities of the clinico-therapeutic use of Bretylium tosylat are demonstrated. The pharmacon is of increasing interest as antiarrhytmic, especially in the commandment of otherwise therapy-refractory ventricular disturbances of rhythm. A positively inotropic effect is proved. More severe side effects, such as arterial hypotension and increase of the pulmonary vascular resistance have an objection to routine application. The antifibrillatory effect needs particular consideration. This effect might promote this pharmacon to the "chemical defibrillator" in the emergency situation.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D001949:Bretylium Compounds / Q000627:therapeutic use*; D001950:Bretylium Tosylate / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004071:Digitalis Glycosides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004344:Drug Incompatibility; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D011802:Quinidine / Q000494:pharmacology; D013268:Stimulation, Chemical; D014655:Vascular Resistance / Q000187:drug effects
D001949:Bretylium Compounds; D004071:Digitalis Glycosides; D001950:Bretylium Tosylate; D011802:Quinidine
Bretylium tosylat als Antiarrhythmikum